Africa Articles
Thursday, July 9, 2026
Empire State Building Observation Deck Launches Exclusive Soccer Jersey Ticket Offer for Sports Fans in July
Robbyant Upgrades and Open-Sources LingBot-VLA 2.0 as a Next-Generation Universal Brain for Embodied AI
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team
(BUSINESS WIRE)--Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team.
"This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side."
At its core, Teamily AI enables humans and AI agents to work together inside one AI-native messenger, creating a new way for teams to achieve compounding intelligence and productivity. Instead of prompting a single assistant, users collaborate with teams of agents that can create, coordinate, and automate real work, including writing slides and documents, building webpage-based product prototypes, standing up monitoring dashboards, running marketing and social media campaigns with closed loop data collection, and more.
The broader goal is to support companies across the full journey of creation and growth, from idea to product to go-to-market, and through the operational work that follows, including market research, competitive analysis, legal research, financial management, fundraising, customer engagement, and team coordination.
The Journey to Teamily AI
Teamily AI is the result of a four-year journey across four major products: FedML, TensorOpera AI, AgentOpera, and Teamily AI.
The foundation began with FedML, the founders’ first startup, which helped enterprises break down data silos and train AI models on private data without merging or exposing that data. The goal from the beginning was to solve real enterprise problems while preserving privacy, security, and control. In early 2024, the team launched TensorOpera AI, building on that private model training foundation to deliver enterprise-grade model serving. TensorOpera AI enabled companies to privately deploy open-source models, customize them with post-training and fine-tuning, and operate them securely in production environments. In 2025, the team introduced AgentOpera, an agentic AI platform for enterprises. AgentOpera brought together an agent hardness layer including multi-model and multi-agent orchestration, memory operating system, MCP connectivity, and tool integration, allowing enterprises to move from individual AI models to coordinated AI agent workflows. Across these three chapters, the platform has served millions of users and helped the team learn what enterprises need most: AI that is not only powerful, but also collaborative, operational, connected, and ready for real work.
Over the past six months, that experience has been productized into Teamily AI. In the last three months alone, Teamily AI completed a major crowdsourced beta, with roughly 20,000 registered seed users and several hundred paying customers testing the full platform and contributing a wealth of product feedback and ideas.
Today, Teamily AI is opening this full stack to everyone, carrying the experience of serving more than 5 million users into a new public platform built to help anyone create and grow a company, from idea to product to go-to-market, and from operations to fundraising and investment.
Product Highlights
Teamily AI combines a full productivity stack, first-class agents, connected context, and living memory to turn everyday conversations into finished, compounding work. The platform delivers seven core capabilities out of the box:
A full productivity stack turns conversations into finished work. Teamily AI goes beyond chat with collaborative studios for web pages, slides, documents, and dashboards, allowing humans and agents to turn conversations into real deliverables. For complex workflows, a messaging-native communication protocol lets people and agents communicate, delegate, and execute together as one team.
First-class agents are ready from day one. Teamily AI builds agents directly into the platform rather than adding limited bots onto a messenger. These agents chat, collaborate, and build alongside users across private conversations, group conversations, collaborative studios, and the public feed. Users can create and customize agents or agent teams in seconds, including AI twins, companions, and collaborators.
One connected context gives agents the full picture. Agents perform best when they share complete context. Teamily AI brings a user’s conversations, relationships, documents, apps, and open ecosystem activity into one connected context, so agents understand the full picture without the user having to repeat information.
Living memory learns from every conversation. Teamily AI treats memory as more than searchable chat history. Its living memory continuously builds, updates, and reorganizes itself from every conversation, learning each user’s knowledge, preferences, taste, and relationships over time.
The best team of models handles every task. Teamily AI replaces a single static model with a context-aware semantic router that selects the best combination of models and agents for each task. This delivers the right balance of speed, cost, and quality based on the user’s goals.
Self improving intelligence gets sharper with use. Teamily AI’s models, agents, and skills continuously improve through real-time human and agent collaboration, making the system more useful the more each team works with it.
A network of shared intelligence means users never start alone. Teamily AI’s public feed lets users discover ideas, remix workflows, fork proven agents, and build on shared intelligence instead of starting from scratch.
Looking Ahead
Teamily AI's vision is to support companies across every stage of their lifecycle with human + AI teams. The platform is designed to help teams move from market research and product strategy to design, development, testing, launch, go-to-market, marketing, customer engagement, and data-driven iteration with closed-loop data collection. It also supports the legal, finance, and fundraising work that runs throughout the company building journey, including market analysis and investor engagement.
Teamily AI’s two co-founders frame that future in their own words:
“We have spent four years building everything from foundational models to the applications on top of them, and we have felt every enterprise pain point firsthand,” said the co-founders of Teamily AI. “Our vision is to accompany a company through its entire lifecycle — from deciding what to build, to designing and shipping the product, to go-to-market, marketing, and even legal, finance, and fundraising. We want building and growing a company to be easy for every team, and we believe humans and agents working together as one team is how that becomes real.”
The development approach is to first let AI create anything such as slides, websites and platforms, products, and web-coded systems, solving the full range of office problems and connecting into a company’s existing systems. From there, atomized foundational capabilities serve every industry: building products, operating companies and products, and driving product growth and enterprise operations across the board. Teamily AI’s two co-founders bring more than four years and five startups of experience. It spans everything from foundational models to top-level applications, giving them deep, firsthand familiarity with enterprise pain points, backed by a team with more than two decades in the internet industry. The team builds outward from a single origin point, the webpage, which lets it connect every step of the journey, using web-based reports and dynamic web systems to carry data-driven presentations, documents, and more.
Teamily AI is now available across web, mobile, and desktop, including iOS, Android, Windows, and Mac. Users can get started at https://teamily.ai or download the app from the App Store and Google Play.
About Teamily AI
Teamily Inc. is an AI platform company headquartered in Palo Alto, California. Its mission is to make building and growing a company easy for every team. Teamily's flagship product, Teamily AI, is the human–AI social platform where humans and AI agents work together for compounding intelligence and productivity. It provides a faster way to turn conversations into creations and automations—from web apps, slide decks, and deep research to dashboards, documents, videos, and more. Built on an AI-native messenger reinvented as the Agent Operating System, Teamily AI is powered by connected context, living memory, and self-improving AI agents that continuously learn and evolve alongside their human teammates. Founded in 2022 by Dr. Aiden Chaoyang He and Professor Salman Avestimehr, Teamily Inc. is backed by leading U.S. venture capital firms.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260708584390/en/
Permalink
https://www.aetoswire.com/en/news/8072026561200
Contacts
Media Contact
Yvonne Li
Media Contact, Teamily AI
Email: contact@teamily.ai
Phone: +1(510)320-3198
Rigaku Opens "Rigaku Solutions Center Osaka" to Strengthen Global Semiconductor Metrology Service Capabilities
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations
DARMSTADT, Germany - Wednesday, 08. July 2026 AETOSWire
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapies
FDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestations
Enpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and review
Not intended for Canada-, UK- or US-based media
(BUSINESS WIRE) -- Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation.
“For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to patients as quickly as possible.”
The FDA Breakthrough Therapy designation is supported by results from the Phase 2 WILLOW study, a multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the safety and efficacy of orally administered enpatoran. The trial used an innovative basket and adaptive study design including patients with both CLE (Cutaneous Lupus Erythematosus) and SLE (Systemic Lupus Erythematosus). The results demonstrated that enpatoran delivered clinically meaningful improvements of lupus symptoms, particularly in patients with active cutaneous manifestations.
Additionally, Merck recently initiated the ELOWEN 1 and ELOWEN 2 studies, a global Phase 3 program evaluating the therapy’s impact on both cutaneous and systemic symptoms in patients with lupus and potential links between skin and systemic disease activity.
Lupus is a chronic autoimmune disease that can affect multiple organ systems, including the skin, joints, kidneys, and central nervous system. Skin manifestations, which can present as inflamed, photosensitive lesions on the face, scalp and other areas, may be life-altering and are sometimes irreversible on their own. But, despite skin manifestations being the first sign of disease in nearly one-third (29%) of lupus cases,1 many patients still do not achieve adequate disease control.2
FDA Breakthrough Therapy designation is a process aimed at expediting the development and review of drugs for serious conditions, where the preliminary clinical evidence indicates that the drug may offer a substantial improvement over available therapy.
About enpatoran
Enpatoran is an investigational, oral, selective inhibitor of toll-like receptors 7 and 8 (TLR7/8), which play a key role in immune pathways involved in lupus. Enpatoran has the potential to be the first targeted therapy for lupus patients with active cutaneous manifestations, with the goal of broadening the treatment paradigm beyond the current standards of care for patients with CLE and SLE. Enpatoran is currently under clinical investigation and has not been approved for any use anywhere in the world.
About the Phase 3 ELOWEN Program
ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218) are two global randomized, double-blind, placebo-controlled Phase 3 studies evaluating enpatoran taken twice daily versus placebo, on top of standard of care, in patients with lupus who have active cutaneous manifestations. The ELOWEN studies will be conducted in 266 sites in 26 countries. Each study will recruit approximately 200 lupus participants, and the primary endpoint will be a change in CLASI-A from baseline.
About Lupus Erythematosus
Lupus erythematosus is a chronic autoimmune disease characterized by inflammation that can affect multiple organs and systems in the body. The disease is heterogeneous, with symptoms ranging from mild to life-threatening, and often follows a relapsing-remitting course.
Cutaneous manifestations are common (72-85%) in patients and can occur alongside or independently of systemic involvement. Beyond their physical presentation, they are associated with increased disease burden, including scarring, psychological impact and reduced quality of life.
Lupus disproportionately affects women and people of color, and many patients continue to experience unmet medical needs due to insufficient disease control or treatment-related side effects.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology. The company’s current neurology portfolio includes two products for the treatment of relapsing MS. Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potential in other neuroinflammatory and immune-mediated diseases, including lupus and generalized myasthenia gravis (gMG).
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. More than 62,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2025, Merck generated sales of € 21.1 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
1 Childs B and Merola JF. From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists. J Clin Aesthet Dermatol. 2025;18(10):40–47.
2 Kandane-Rathnayake R, Louthrenoo W, Hoi A, et al. ‘Not at target’: prevalence and consequences of inadequate disease control in systemic lupus erythematosus—a multinational observational cohort study. Arthritis Res Ther. 2022;24(1):70.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260706387547/en/
Permalink
https://www.aetoswire.com/en/news/0807202656114
Contacts
Sebastian Roos
sebastian.roos@merckgroup.com
Phone: +49 151 14 54 1721
NetApp Named Presenting Partner of 2026 NFL Madrid Game
MADRID -
League’s Official Intelligent Data Infrastructure Partner Extends Its Presence Across the NFL’s International Games
(BUSINESS WIRE)--The NFL today announced that the league’s Global Partner, NetApp (NASDAQ: NTAP), the Intelligent Data Infrastructure company, will return as Presenting Partner of the 2026 NFL Madrid Game, featuring the Atlanta Falcons taking on the Cincinnati Bengals at the Bernabéu Stadium — home to Real Madrid C.F. — on Sunday, Nov. 8.
The multi-year announcement builds on NetApp’s role as the league’s Official Intelligent Data Infrastructure Partner and Presenting Partner of the inaugural NFL Madrid Game in 2025 and continues the company’s support of the league’s international games.
“We are delighted to welcome NetApp back as Presenting Partner of the NFL Madrid Game,” said Rafa De Los Santos, country manager of NFL Spain. “Last year’s game at the Bernabéu was a landmark moment for the NFL in Spain, and with the Falcons and Bengals bringing two of the most exciting teams in football to Madrid this November, we look forward to working with NetApp to deliver another unforgettable experience for our fans.”
“Football fans want a consistently great experience whether their team is playing in their home stadium or on another continent,” said César Cernuda, President at NetApp. “The key is intelligent data that is accessible, protected and fast, no matter where the game takes place. As the NFL expands its international presence, NetApp is helping it build data infrastructure that meets the high standards of the NFL.”
NetApp became the NFL’s Official Intelligent Data Infrastructure Partner in April 2025, working with the league to make its data intelligent with powerful and secure infrastructure while activating across the NFL’s international games, including as Presenting Partner of the NFL London Games. The NFL trusts NetApp to build and implement an intelligent data infrastructure that supports league operations, including the storage and security of large volumes of gameday video from every NFL game.
NetApp will also serve as the Presenting Partner for the 2026 NFL London Games:
Week 4: Indianapolis Colts vs. Washington Commanders (Oct. 4 at Tottenham Hotspur Stadium)
Week 5: Philadelphia Eagles vs. Jacksonville Jaguars (Oct. 11 at Tottenham Hotspur Stadium)
Week 6: Houston Texans vs. Jacksonville Jaguars (Oct. 18 at Wembley Stadium)
The 2026 NFL Madrid Game is one of nine international games this season, with the league also playing in Melbourne, Rio de Janeiro, London, Paris, Munich and Mexico City.
NFL Madrid Game tickets are available to purchase on the following dates:
From June 5 – Hospitality Packages Available
From July 9 – General Admission Opens
Fans can sign up for the latest updates around the game and ticketing information at nfl.com/Madrid. To stay up to date on everything about the NFL in Spain, follow @nflespana on Instagram and TikTok.
For more information on all NFL international games, fans can visit nfl.com/internationalgames.
About NetApp
For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.
At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.
Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.
With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.
Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260708683997/en/
Permalink
https://www.aetoswire.com/en/news/8072026561099
Contacts
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Kris Newton
NetApp
kris.newton@netapp.com
Wednesday, July 8, 2026
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands
(BUSINESS WIRE)--Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region.
“APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Kath Harrison, Group President, International Growth at Real Chemistry. “By bringing Spurwing into Real Chemistry, we’re expanding our presence in the region and deepening our ability to help clients drive measurable impact by delivering more connected, data-driven and culturally relevant engagement across these key markets.”
Founded in Singapore, Spurwing Communications is a leading agency with an established track record advising pharmaceutical and healthcare organizations — as well as clients across a broader range of industries — throughout APAC. The company is known for high-impact strategic counsel across integrated communications, medical affairs and its nuanced understanding of the region’s diverse and evolving market environments.
Emma Thompson, Founder and Chief Executive Officer (CEO) of Spurwing Communications, will continue to lead the business as President, APAC Growth, reporting to Harrison. “Joining Real Chemistry allows us to broaden what we can offer clients, while staying grounded in the strong regional expertise and senior counsel for which our clients value us,” said Thompson. “I’m extremely proud of what we have achieved as a team and excited for the next phase of our growth as part of Real Chemistry. We will continue to support our existing clients while expanding our APAC presence and adding capabilities — including analytics and AI — to enhance our connected, comprehensive regional offerings.”
“Real Chemistry’s acquisition of Spurwing Communications is an important step in our global growth strategy,” said Shankar Narayanan, CEO of Real Chemistry. “We’re continuing to invest in the capabilities and regions that matter most to our clients as they navigate growing global commercialization challenges. Strengthening our presence in APAC allows us to better support clients across the full lifecycle — from strategy through engagement — in one of the most dynamic healthcare markets in the world.”
Additional hires and market expansion plans are expected to be announced over the coming months, as Real Chemistry continues to scale its regional hub model and affiliate network across key international markets.
About Real Chemistry: 25 Years of Future-Focused Healthcare
Celebrating its 25th anniversary this year, Real Chemistry is a tier-one commercialization partner to the world’s most innovative life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, Real Chemistry helps the healthcare industry better understand, reach and engage critical audiences to improve the healthcare experience for all. Anchored by a culture of innovation and creativity, Real Chemistry’s 2,400+ global experts across life sciences, marketing communications and technology are singularly focused on navigating the complexities of bringing scientific advances to market — and to the people who need them most. Real Chemistry’s brand portfolio includes 21GRAMS, a highly awarded creative agency, and starpower, a celebrity and influencer practice.
Today, Real Chemistry operates through offices across North America, Europe, the Middle East and Asia Pacific, complemented by a strategic partner network in Latin America and Africa — enabling the company to support clients wherever they operate.
Learn more at www.realchemistry.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260706477680/en/
Permalink
https://www.aetoswire.com/en/news/54565566
Contacts
Media:
media@realchemistry.com